Company: CERO
Filing Date: 2025-12-05
Form Type: S-1
Source: 0001213900-25-118817
Chunk: 277

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-12-05
Form: S-1
Chunk 277
---
4, and previously served as Chief       
 Executive Officer, Chief Scientific Officer, and a member of the board of directors of Legacy CERo until the closing of the Business 
 Combination in February 2024.                                                                                                        |

| (3) | Brian G. Atwood served as                                                                                                         
 Chairman and Chief Executive Officer from February 2024 to September 2024, and previously served as Chairman of PBAX until        
 the closing of the Business Combination in February 2024 Mr. Atwood is a member of the board of directors and serves as a trustee 
 of Atwood-Edminster Trust dtd 4-2-2000.                                                                                           |

164

| (4) | Chris Ehrlich has served as the                                                                                                
 Chairman and Chief Executive Officer since December 2024, and previously served as (i) interim Chairman and Chief Executive    
 Officer from October 2024 to November 2024, (ii) Vice Chairman of the board of directors from February 2024 to September 2024, 
 and (iii) the Chief Executive Officer of PBAX until the closing of the Business Combination in February 2024.                  |

| (5) | Phoenix Biotech Sponsor, LLC beneficially                                           
 owned more than 5% of our outstanding capital stock at the time of the transaction. |

Registered Direct Offering in February 2025 On February 7, 2025, we issued and sold 15,000 shares of our Common Stock and 112,551 Pre-Funded Warrants to purchase 112,551 shares of our Common Stock together with 127,551 February 2025 Common Warrants to purchase 127,551 shares of Common Stock. Each share of Common Stock or Pre-Funded Warrant is being sold together with a February 2025 Common Warrant to purchase one share of Common Stock. The shares of Common Stock or Pre-Funded Warrants and accompanying February 2025 Common Warrants were issued separately and were immediately separable upon issuance. Brian Atwood, one of our directors, purchased an aggregate of 25,510 Pre-Funded Warrants and accompanying February 2025 Common Warrants to purchase 25,510 shares of Common Stock for a total purchase price of approximately $1 million at this offering. Other On April 22, 2025, pursuant to the Fourth Securities Purchase Agreement, the Company issued and sold, and the investors purchased, in a private placement (the “Fourth PIPE Financing”), 6,250 shares of the Series D